{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000051","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-08-26T22:24:21+00:00","discovered_at":"2026-08-27T10:05:00.237406+00:00","generated_at":"2026-08-27T10:05:24.187213+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina enters $25M equity purchase agreement with Roth Principal Investments","bullets":["Up to $25M of new common stock can be sold to Roth Principal over 36 months at 3-7% discount to VWAP.","Sales are at Serina's sole discretion; no obligation to sell; proceeds for working capital.","Exchange cap of 5,077,554 shares (19.99% of outstanding) unless price >= $2.7695 or stockholder approval.","Roth Principal barred from short sales; Serina pays $100K legal fees plus $7.5K/quarter.","Registration rights agreement filed; Compass Point engaged as qualified independent underwriter."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000051","json":"https://secwatch.observer/filing/0001708599-26-000051.json","markdown":"https://secwatch.observer/filing/0001708599-26-000051.md","text":"https://secwatch.observer/filing/0001708599-26-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/0001708599-26-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/ser-20260821.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-27T10:05:24.187213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}